Equities Analysts Issue Forecasts for Soligenix Q3 Earnings

Soligenix Inc. (NASDAQ:SNGX) – Equities researchers at Zacks Small Cap boosted their Q3 2025 earnings estimates for shares of Soligenix in a research report issued on Tuesday, September 30th. Zacks Small Cap analyst D. Bautz now forecasts that the biopharmaceutical company will earn ($0.63) per share for the quarter, up from their prior estimate of ($0.82). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($3.02) EPS, FY2026 earnings at ($1.68) EPS and FY2027 earnings at ($1.50) EPS.

Soligenix (NASDAQ:SNGX) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.03).

SNGX has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a research note on Saturday, September 27th. Alliance Global Partners lowered their target price on Soligenix from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, July 16th. Finally, Wall Street Zen cut shares of Soligenix to a “strong sell” rating in a report on Saturday, August 16th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $6.00.

Soligenix Stock Performance

Shares of SNGX opened at $1.38 on Friday. Soligenix has a 52-week low of $1.09 and a 52-week high of $6.23. The business’s fifty day moving average is $2.61 and its 200-day moving average is $2.08. The firm has a market cap of $5.92 million, a price-to-earnings ratio of -0.36 and a beta of 1.95.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Soligenix stock. Connective Capital Management LLC purchased a new position in shares of Soligenix Inc. (NASDAQ:SNGX) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 101,633 shares of the biopharmaceutical company’s stock, valued at approximately $219,000. Connective Capital Management LLC owned 3.11% of Soligenix at the end of the most recent quarter. 3.60% of the stock is currently owned by institutional investors and hedge funds.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.